Description
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer
Endopredict
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer
TAT:
Specimen Type:
Genomics Single Test
Other Tests
- 237%
-
264%
Oncoprint
Hotspot genes: ABL1, BRAF, CBL, CSF3R, DNMT3A, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NPM1, NRAS, PTPN11, SETBP1, SF3B1, SRSF2, U2AF1, WT1. Full Genes: ASXL1, BCOR, CALR, CEBPA, ETV6, EZH2, IKZF1, NF1, PHF6, PRPF8, RB1, RUNX1, SH2B3, STAG2, TET2, TP53, ZRSR2. Fusion Driver Genes: ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6 (TEL), FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A(MLL), MECOM, MET, MLLT10, MLLT3, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM16, RUNX1 (AML1), TCF3(E2A), TFE3
Oncoprint
Hotspot genes: ABL1, BRAF, CBL, CSF3R, DNMT3A, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NPM1, NRAS, PTPN11, SETBP1, SF3B1, SRSF2, U2AF1, WT1. Full Genes: ASXL1, BCOR, CALR, CEBPA, ETV6, EZH2, IKZF1, NF1, PHF6, PRPF8, RB1, RUNX1, SH2B3, STAG2, TET2, TP53, ZRSR2. Fusion Driver Genes: ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6 (TEL), FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A(MLL), MECOM, MET, MLLT10, MLLT3, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM16, RUNX1 (AML1), TCF3(E2A), TFE3
-
264%
OncQuer TM Scout LB EGFR Sensitivity Test
Identification gene mutations leading to sensitivity to EGFR therapy
OncQuer TM Scout LB EGFR Sensitivity Test
Identification gene mutations leading to sensitivity to EGFR therapy
-
264%
OncQuer TM Scout LB EGFR Resistance Test
Identification gene mutations leading to resistance to EGFR therapy
OncQuer TM Scout LB EGFR Resistance Test
Identification gene mutations leading to resistance to EGFR therapy
Reviews
There are no reviews yet.